{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:45:12Z","timestamp":1759063512261},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The SARS-CoV-2 virus has been raging globally for over 2\u00a0years with no end in sight. It has become clear that this virus possesses enormous genetic plasticity, and it will not be eradicated. Under increasing selective pressure from population immunity, the evolution of SARS-CoV-2 has driven it towards greater infectivity, and evasion of humoral and cellular immunity. Omicron and its expanding army of subvariants and recombinants have impaired vaccine protection and made most antibody drugs obsolete. Antiviral drugs, though presently effective, may select for more resistant strains over time. It may be inevitable, then, that future SARS-CoV-2 variants will be immune to our current virus-directed countermeasures. Thus, to gain control over the virus, we need to adopt a new paradigm in searching for next-generation countermeasures and develop host-directed therapeutics (HDTx) and host-directed antivirals (HDA). Different from the virus-directed countermeasures, HDTx and HDA may offer variant agnostic treatment to reduce the risk and severity of infections. In addition, they may exert more uniform effects against the genetically diverse SARS-CoV-2 quasispecies, thereby diminishing the risk of selecting resistant variants. Some promising HDTx and HDA approaches are summarized here.<\/jats:p>","DOI":"10.1186\/s12985-022-01887-y","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T16:04:07Z","timestamp":1665417847000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["As the virus evolves, so too must we: a drug developer\u2019s perspective"],"prefix":"10.1186","volume":"19","author":[{"given":"Fang Flora","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"1887_CR1","doi-asserted-by":"crossref","unstructured":"Mallapaty S. COVID reinfections surge during Omicron onslaught. 2022. https:\/\/www.nature.com\/articles\/d41586-022-00438-3.","DOI":"10.1038\/d41586-022-00438-3"},{"key":"1887_CR2","unstructured":"covSPECTRUM collection #24 Tracking\/Designated Lineages. https:\/\/cov-spectrum.org\/collections\/24"},{"key":"1887_CR3","doi-asserted-by":"publisher","unstructured":"Jankowiak M, Obermeyer FH, Lemieux JE. Inferring selection effects in SARS-CoV-2 with Bayesian Viral Allele Selection. 2022. Preprint at. https:\/\/doi.org\/10.1101\/2022.05.07.490748v2.","DOI":"10.1101\/2022.05.07.490748v2"},{"key":"1887_CR4","doi-asserted-by":"crossref","unstructured":"Saito A, Tamura T, Zahradnik J, Deguchi S, Tabata K, Kimura I, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75. 2022. Preprint at. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.08.07.503115v1.","DOI":"10.1101\/2022.08.07.503115"},{"key":"1887_CR5","doi-asserted-by":"publisher","unstructured":"Sugano A, Takaoka Y, Kataguchi H, Kumaoka M, Ohta M, Kimura S, et al. SARS-CoV-2 Omicron BA.2.75 variant may be much more infective than preexisting variants. 2022. Preprint at bioRxiv. https:\/\/doi.org\/10.1101\/2022.08.25.505217.","DOI":"10.1101\/2022.08.25.505217"},{"key":"1887_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/22221751.2021.2023330","volume":"11","author":"FF Fang","year":"2022","unstructured":"Fang FF, Shi PY. Omicron: a drug developer\u2019s perspective. Emerg Microbes Infect. 2022;11:208\u201311.","journal-title":"Emerg. Microbes Infect."},{"key":"1887_CR7","doi-asserted-by":"publisher","first-page":"pgac049","DOI":"10.1093\/pnasnexus\/pgac049","volume":"1","author":"H Zhao","year":"2022","unstructured":"Zhao H, Nguyen A, Wu D, Li Y, Hassan SA, Chen J, et al. Plasticity in structure and assembly of SARS-CoV-2 nucleocapsid protein. PNAS Nexus. 2022;1:pgac049.","journal-title":"PNAS Nexus"},{"key":"1887_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/v14010078","volume":"14","author":"GD Amoutzias","year":"2022","unstructured":"Amoutzias GD, et al. The remarkable evolutionary plasticity of coronaviruses by mutation and recombination: insights for the COVID-19 pandemic and the future evolutionary paths of SARS-CoV-2. Viruses. 2022;14:78.","journal-title":"Viruses"},{"key":"1887_CR9","doi-asserted-by":"crossref","unstructured":"Shiraz R, Tripathi S. Enhanced recombination among SARS-CoV-2 Omicron variants contributes to viral immune escape. 2022. Preprint at. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.08.23.504936v1.","DOI":"10.1101\/2022.08.23.504936"},{"key":"1887_CR10","doi-asserted-by":"crossref","unstructured":"Lythgoe KA, Golubchik T, Hall M, House T, Maclntyre-Cockett G, Fryer H, et al. Lineage replacement and evolution captured by the United Kingdom Covid Infection Survey.2022. Preprint at. https:\/\/medrxiv.org\/content\/10.1101\/2022.01.05.21268323v1.","DOI":"10.1101\/2022.01.05.21268323"},{"key":"1887_CR11","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1038\/s41467-022-30884-6","volume":"13","author":"T Patalon","year":"2022","unstructured":"Patalon T, Saciuk Y, Peretz A, Perez G, Lurie Y, Maor Y, et al. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nature Commun. 2022;13:3203.","journal-title":"Nature Commun"},{"key":"1887_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071113","volume":"377","author":"S Gazit","year":"2022","unstructured":"Gazit S, Saciuk Y, Perez G, Peretz A, Pitzer VE, Patalon T. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. BMJ. 2022;377: e071113.","journal-title":"BMJ"},{"key":"1887_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000726","volume":"9","author":"T Assawasaksakul","year":"2022","unstructured":"Assawasaksakul T, Sathitratanacheewin S, Vichaiwattana P, Wanlapakorn N, Poovorawan Y, Avihingsanon Y, et al. Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis. Lupus Sci Med. 2022;9: e000726.","journal-title":"Lupus Sci Med"},{"key":"1887_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.08.003","author":"C Saggau","year":"2022","unstructured":"Saggau C, Martini GR, Rosati E, Meise S, Messner B, Kamps AK, et al. The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination. Immunity. 2022. https:\/\/doi.org\/10.1016\/j.immuni.2022.08.003.","journal-title":"Immunity"},{"key":"1887_CR15","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593\u2013602.","journal-title":"Nature"},{"key":"1887_CR16","doi-asserted-by":"crossref","unstructured":"Scheaffer SM, Lee D, Whitener B, Ying B, Wu K, Jani H, et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant. 2022. Preprint at. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.09.12.507614v1.","DOI":"10.1101\/2022.09.12.507614"},{"key":"1887_CR17","unstructured":"Bert NL, Tan A, Kunasegaran K, Chia A, Tan N, Chen Q, et al. Mutations of SARS-CoV-2 variants of concern escaping Spike-specific T cells. 2022. Preprint at. https:\/\/biorxiv.org\/content\/10.1101\/2022.01.20.477163v1."},{"key":"1887_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009726","volume":"18","author":"A Foix","year":"2022","unstructured":"Foix A, Lopez D, Diez-Fuertes F, McConnell M, Martin-Galiano AJ. Predicted impact of the viral mutational landscape on the cytotoxic response against SARS-CoV-2. PLoS Comput Biol. 2022;18: e1009726.","journal-title":"PLoS Comput Biol"},{"key":"1887_CR19","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cell.2022.01.029","volume":"185","author":"V Naranbhai","year":"2022","unstructured":"Naranbhai V, Nathan A, Kaseke C, Berrios C, Khatri A, Choi S, et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022;185:1041\u201351.","journal-title":"Cell"},{"key":"1887_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2201933","author":"E Takashita","year":"2022","unstructured":"Takashita E, Kinoshita N, Yamayoshi S, Sakai-tagawa Y, Fujisaki S, Ito M, et al. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMc2201933.","journal-title":"N Engl J Med"},{"key":"1887_CR21","doi-asserted-by":"crossref","unstructured":"Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. 2022. Preprint at. https:\/\/biorxiv.org\/content\/10.1101\/2021.04.30.442182v6.full.","DOI":"10.1101\/2021.04.30.442182"},{"key":"1887_CR22","doi-asserted-by":"crossref","unstructured":"Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J, et al. Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies. 2022. Preprint at. https:\/\/biorxiv.org\/content\/10.1101\/2022.05.03.490409v1.","DOI":"10.1101\/2022.05.03.490409"},{"key":"1887_CR23","doi-asserted-by":"crossref","unstructured":"Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. 2022. Preprint at. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.09.15.507787v1.","DOI":"10.1101\/2022.09.15.507787"},{"key":"1887_CR24","doi-asserted-by":"crossref","unstructured":"Witte L, Baharani V, Schmidt F, Wang Z, Cho A, Raspe R, et al. Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape. 2022. Preprint at. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.08.17.504313v1.","DOI":"10.1101\/2022.08.17.504313"},{"key":"1887_CR25","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77433","volume":"11","author":"JM Flynn","year":"2022","unstructured":"Flynn JM, et al. Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. Elife. 2022;11: e77433.","journal-title":"Elife"},{"key":"1887_CR26","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","volume":"13","author":"AM Shaqra","year":"2022","unstructured":"Shaqra AM, Zvornicanin SN, Huang QYJ, Lockbaum GJ, Knapp M, Tandeske L, et al. Defining the substrate envelope of SARS-CoV-2 Main protease to predict and avoid drug resistance. Nature Commun. 2022;13:3556.","journal-title":"Nature Commun"},{"issue":"8","key":"1887_CR27","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3390\/molecules27082523","volume":"27","author":"L Agost-Beltr\u00e1n","year":"2022","unstructured":"Agost-Beltr\u00e1n L, de la Hoz-Rodr\u00edguez S, Bou-Iserte L, Rodr\u00edguez S, Fern\u00e1ndez-de-la-Pradilla A, Gonz\u00e1lez FV. Advances in the development of SARS-CoV-2 Mpro inhibitors. Molecules. 2022;27(8):2523. https:\/\/doi.org\/10.3390\/molecules27082523.","journal-title":"Molecules"},{"key":"1887_CR28","doi-asserted-by":"crossref","unstructured":"Hu Y, Lewandowski EM, Tan H, Morgan RT, Zhang X, Jacobs LMC, et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. 2022. Preprint at. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.06.28.497978v1.","DOI":"10.1101\/2022.06.28.497978"},{"key":"1887_CR29","doi-asserted-by":"crossref","unstructured":"Moghadasi SA, Heilmann E, Moraes SN, Kearns FL, von Laer D, Amaro RE, et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. 2022. Preprint at. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.08.07.503099v1.","DOI":"10.1101\/2022.08.07.503099"},{"key":"1887_CR30","doi-asserted-by":"publisher","first-page":"eabo0718","DOI":"10.1126\/scitranslmed.abo0718","volume":"14","author":"LJ Stevens","year":"2022","unstructured":"Stevens LJ, Pruijssers AJ, Lee HW, Gordon CJ, Tchesnokov EP, Gribble J, et al. Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci Transl Med. 2022;14:eabo0718.","journal-title":"Sci Transl Med"},{"key":"1887_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1010200","volume":"18","author":"ER Chan","year":"2022","unstructured":"Chan ER, Jones LD, Linger M, Kovach JD, Torres-Teran MM, Wertz A, et al. COVID19 infection and transmission includes complex sequence diversity. PLoS Genet. 2022;18: e1010200.","journal-title":"PLoS Genet"},{"key":"1887_CR32","unstructured":"NIH COVID-19 treatment guidelines\/Immunomodulators. https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/immunomodulators\/."},{"key":"1887_CR33","unstructured":"Systemic Corticosteroids: Selected Clinical Data. https:\/\/www.covid19treatmentguidelines.nih.gov\/tables\/systemic-corticosteroids-data\/."},{"issue":"7","key":"1887_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270668","volume":"17","author":"PJ Godolphin","year":"2022","unstructured":"Godolphin PJ, Fisher DJ, Berry LR, Derde LPG, Diaz JV, Gordon AC, et al. Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: a network meta-analysis. PLoS ONE. 2022;17(7): e0270668.","journal-title":"PLoS ONE"},{"key":"1887_CR35","unstructured":"FDA approves Lilly and Incyte\u2019s OLUMIANT\u00ae (baricitinib) for the treatment of certain hospitalized patients with COVID-19. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-lilly-and-incytes-olumiantr-baricitinib-treatment Accessed 11 May 2022."},{"key":"1887_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00088-1","author":"CR Wolfe","year":"2022","unstructured":"Wolfe CR, Tomashek KM, Patterson TF, Gomez CA, Marconi VC, Jain MK, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022. https:\/\/doi.org\/10.1016\/S2213-2600(22)00088-1.","journal-title":"Lancet Respir Med"},{"key":"1887_CR37","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","volume":"183","author":"TM Clausen","year":"2020","unstructured":"Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell. 2020;183:1043\u201357.","journal-title":"Cell"},{"key":"1887_CR38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/v13030384","volume":"13","author":"M Kishimoto","year":"2021","unstructured":"Kishimoto M, Uemura K, Sanaki T, Sato A, Hall WW, Kariwa H, et al. TMPRSS11D and TMPRSS13 activate the SARS-CoV-2 spike protein. Viruses. 2021;13:384.","journal-title":"Viruses"},{"key":"1887_CR39","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.3390\/cells9112377","volume":"9","author":"D Bojkova","year":"2020","unstructured":"Bojkova D, Bechtel M, McLaughlin KM, McGreig JE, Klann K, Bellinghausen C, et al. Aprotinin inhibits SARS-CoV-2 replication. Cells. 2020;9:2377\u201389.","journal-title":"Cells"},{"key":"1887_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2327-5073.1000238","volume":"5","author":"M Yamaya","year":"2016","unstructured":"Yamaya M, Shimotai Y, Hatachi Y, Homma M, Nishimura H. Serine proteases and their inhibitors in human airway epithelial cells: effects on influenza virus replication and airway inflammation. Clin Microbiol. 2016;5:2.","journal-title":"Clin Microbiol"},{"key":"1887_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13776","volume":"52","author":"FJ Redondo-Calvo","year":"2022","unstructured":"Redondo-Calvo FJ, Padin JF, Munoz-Rodriguez JR, Serrano-Oviedo L, Lopez-Juarez P, Leal MLP, et al. Aprotinin treatment against SARS-CoV-2: a randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID19. Eur J Clin Invest. 2022;52: e13776.","journal-title":"Eur J Clin Invest"},{"key":"1887_CR42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41586-022-04661-w","volume":"605","author":"T Shapira","year":"2022","unstructured":"Shapira T, Monreal IA, Dion SP, Buchholz DW, Imbiakha B, Olmstead AD, et al. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature. 2022;605:340\u20138.","journal-title":"Nature"},{"key":"1887_CR43","doi-asserted-by":"publisher","first-page":"18579","DOI":"10.1074\/jbc.RA120.015303","volume":"295","author":"J Lu","year":"2020","unstructured":"Lu J, Sun P. High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. J Bio Chem. 2020;295:18579\u201388.","journal-title":"J Bio Chem"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-022-01887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-022-01887-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-022-01887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T16:29:54Z","timestamp":1678206594000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-022-01887-y"}},"subtitle":["We need a new paradigm in searching for next-generation countermeasures"],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1887"],"URL":"https:\/\/doi.org\/10.1186\/s12985-022-01887-y","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"26 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}